P.01/06

Procter & Gamble - I.P. Division

RECEIVED CENTRAL FAX CENTER

IMPORTANT CONFIDENTIALITY NOTICE

MAY 0 3 2004

The documents accompanying this telecopy transmission contain confidential information belonging to the sender which is legally protected. The information is intended only for the use of the individual or entity named below. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telecopied information is strictly prohibited. If you have received this telecopy in error, please immediately notify us by telephone (collect) to arrange for return of the telecopied document to us.

FACSIMILE TRANSMITTAL SHEET AND CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8

TO: United States Patent and Trademark Office

Fax No. (703) 872-9306

Phone No. (703) 308-4710

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on April 30, 2004, to the above-identified facsimile number.

FROM: Joan B. Cunningham

Fax No. (513) 622-3300

Phone No. (513) 622-3993

Number of Pages Including this Page: 6

Listed below are the item(s) being submitted with this Certificate of Transmission:

1) Fee Transmittal (1 page)

Inventor(s): Douglas Joseph Dobrozsi

S.N.:

09/361,542

2) Petition for Extension of Time (1 page)

Filed:

July 27, 1999

Response Under 37 CFR 1.111 (3 pgs.)

Case:

7247M

4)

Comments:

(\$950)

TOTAL AMOUNT OF PAYMENT

U.S. Putent and Trademark Office: U.S. DEPARTMENT OF COMMERCE d to a collection of information unless it displays a valid OMB control number

FEE TRANSMITTAL	Complete if Known			
for FY 2004	Application Number	09/361,542		
Patent fees are subject to annual revision.	Confirmation Number	5652		
	Filing Date	July 27, 1999		
	First Named Inventor	Douglas J. Dobrozsi		
	Examiner Name	A. Pulliam		
	Art Unit	1615		

Attorney Docket No.

7247M

METHOD OF PAYMENT	FEE CALCULATION (continued)				
The Director is hereby authorized to charge indicated fees submitted on this form, credit any over payments, and charge my	3. ADDITIONAL FEES				
additional fee(s) during the pendency of this application to:	Code (\$) Fee Description Fee Paid				
	1051 130 Surcharge-late filing fee or oath []				
Deposit Account Number: 16-2480	1052 50 Surcharge-late provisional filing fee or cover sheet []				
Deposit Account Name: The Procter & Gamble Company	1053 130 Non-English specification []				
	1812 2,520 For filing a request for ex parte reexamination []				
	1804 920* Requesting publication of STR prior to				
	Examiner's action []				
FEE CALCULATION	1805 1,840* Requesting publication of SIR after				
	Examiner's action []				
1. BASIC FILING FEE - Large Entity	1251 110 Extension for reply within 1" month []				
•	1252 420 Extension for reply within 2 nd month []				
Code (\$) Fee Description Fee Paid	1253 950 Extension for reply within 3 rd month [X]				
1001 770 Utility filing fee []	1254 1,480 Extension for reply within 4th month				
1002 340 Design filing fee []	1255 2,010 Extension for raply within 5th month []				
1004 770 Reissur filing fee []	1401 330 Notice of Appeal []				
1005 160 Provisional filing fee	1402 330 Filing a brief in support of an appeal []				
•	1403 290 Request for oral hearing []				
SUBTOTAL (1) (5)()	1451 1,510 Pedition to institute a public use proceeding []				
	1452 110 Petition to revive - unavoidable []				
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE - Large Entity	1453 1,330 Petition to revive - unintentional []				
	1501 1,330 Utility issue fee (or reissue) []				
Extra Pee from Pee	1502 480 Design issue fee []				
<u>Claims Below Paid</u>	1460 130 Petitions to the Commissioner []				
Total Claims [] • 20** = [] x [] =[]	1807 50 Processing fee under 37 C.F.R. 1.17(q)				
Independent Claims [] - 3** = [] x [] =[]	1806 180 Submission of Information Disclosure Statement []				
Multiple Dependent [] =[]	1809 770 Filing a submission after final rejection				
** or number previously paid, if greater: For Reissuea, see below	(37 CFR § 1.129(n)) []				
	1810 770 For each additional invention to be				
Code (5) <u>Fee Description</u>	examined (37 CFR §1.129(b) ()				
1202 18 Claims in excess of 20	1801 770 Request for Continued Examination (RCE) []				
1201 86 Independent claims in excess of 3	1802 900 Request for expedited examination [] of a design application				
1203 290 Multiple dependent claim, if not paid	1454 1330 Acceptance of unintentionally delayed claim for []				
1204 86 **Reissue independent claims over original patent	priority under 35 U.S.C. 119, 120, 121, or 365 (a) or (c)				
1205 18 **Reissue claims in excess of 20 & over original patent					
,	Other fee (specify)				
,	Other fee (specify)				
SUBTOTAL (2) (\$)(1	* Reduced by Basic Filing Fee Paid SUBTOTAL(3) (\$950) []				

SUBMITTED BY			Complete (if applicable)		
Name (Print/Type)	Joan B. Cunningham	Registration No. (Attorney/Ageat)	43,962	Telephone	(513) 622-3993
Signature	Joan B. Cua	ningham	>	Date	April 30, 2004

This collection of information by Fig. 1.17. The information is equired to obtain or letaln a benefit by the public which is to file (and by the USPTO to process) an application.

Confidentiality is governed by 36 U.S.C. 122 and 37 CFR 1.14. This collection is entimated to date 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. This will very depending upon additional case. Any comments on the amount of time you are required to complete this form another suggestions for reducing this burden, should be seen to the Chief Information Officer, U.S. Patients and Trademark Officer, U.S. Department of Continence, P. O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND PLES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.Q. Box 1450, Alexandria, VA 22313-1450.

Fectives-like (Revised for P&C use 9/22/1003)

Case 7247M

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of

Douglas J. Dobrozsi :

.

Group Art Unit: 1615

MAY 0 3 2004

RECEIVED

CENTRAL FAX CENTER

Confirmation No.: 5652 Filed: July 27, 1999

Serial No.: 09/361,542

: Examiner: A. Pulliam

Title: Oral Liquid Mucoadhesive Compositions



RESPONSE UNDER 37 CFR 1.111

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

In response to the October 31, 2003 Office Action in the above-identified case, please consider the following remarks.

REMARKS

Claims 36, 38-39, 41-46, and 48 remain in the present application. Claims 1-35, 37, 40, and 47 have been previously canceled. No additional claims fee is believed to be due.

Invention Synopsis

The present invention is directed to oral, liquid, aqueous, mucoretentive compositions, and a method of administering such compositions, wherein the compositions comprise colloidal particles of silicon dioxide, a select pharmaceutical active, and a citric acid.

It has been found that prolonged and improved coating and protection of components of the alimentary canal such as the stomach, esophagus, and small intestine can be achieved by incorporating a mucoadhesive material into an oral pharmaceutical composition. Unlike conventional mucoadhesive materials such as mucoadhesive polymers, the compositions of the present invention comprise a silicon dioxide which provides for highly effective mucoadhesive systems. It has also been found that when the compositions of the present invention comprise a citric acid, the solid particles of these highly effective mucoadhesive systems are consistently dispersed to result in improved stability of the systems.

Art Rejection

Claims 36, 38-39, 41-46, and 48 have been rejected under 35 U.S.C. 103 as being unpatentably obvious over the product Silicol* (manufactured by Saguna GmbH in Germany) in view of Banning et